Clinical trial NCT04792333: Pharmacokinetics in End Stage Renal Disease Patients
Official title: A Phase I Study to Compare Pharmacokinetic Parameters of Firibastat and Its Metabolites (EC33 and QGC515) in Healthy Subjects Versus End Stage Renal Disease (ESRD) Patients After a Single Oral Administration of Firibastat 500 mg
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy Volunteers
Renal Failure
Lead sponsor: Quantum Genomics SA
Sponsor class: INDUSTRY
Collaborators: name: Eurofins Optimed
First posted: 2021-03-10
Enrollment: 28
Sex: MALE
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: The study is a multicentre, open label, phase I, two arms study to compare pharmacokinetic of firibastat after a single oral dose of firibastat 500 mg in fourteen healthy male volunteers and in fourteen End Stage Renal Disease (ESRD) patients not yet in dialysis.

Detailed description: It is planned to enroll a total of 28 subjects to receive a single oral dose of investigational medicinal product (IMP): 14 ESRD patients will be enrolled in three Hungarian centres (1st arm) and 14 Healthy volunteers will be enrolled by Eurofins Optimed in Gières, France (2nd arm).

Subjects will be screened for eligibility to participate in the study up to 21 days prior to the first administration. For both arm, subjects will be admitted into the Clinical Research Unit (CRU) on Day -3. On the morning of Day 1, subjects will receive a single 500 mg oral dose of firibastat following an overnight fast (i.e., at least 10 hours). Subjects will be confined to the CRU until discharge on Day 3 with PK blood sample draws for measurement of firibastat and its main metabolites being taken throughout the confinement.

A follow-up post study visit will occur on Day 10 post-dose to ensure the ongoing wellbeing of the subjects.

Eligibility criteria: Inclusion Criteria:

* Male subjects, aged 18 to 55 years inclusive;
* Non-smoker subject or smoker of not more than 5 cigarettes a day;

Exclusion Criteria:

* Positive Hepatitis B surface (HBs) antigen or anti Hepatitis C Virus (HCV) antibody, or positive results for Human Immunodeficiency Virus (HIV) 1 or 2 tests);
* History or presence of drug or alcohol abuse (alcohol consumption \> 40 grams/day);

Primary outcomes:
measure: Firibastat and metabolites Concentrations
timeFrame: Day 1 to Day 3
Secondary outcomes:
measure: Systolic and Diastolic Blood Pressure (mmHg)
timeFrame: Day 1 to Day 3
measure: Heart Rate (bpm)
timeFrame: Day 1 to Day 3
measure: Hematology blood sample laboratory tests aggregated as number of patients outside ranges
timeFrame: Day 1 to Day 3
measure: Biochemistry blood sample laboratory tests aggregated as number of patients outside ranges
timeFrame: Day 1 to Day 3
measure: Hemostasis blood sample laboratory tests aggregated as number of patients outside ranges
timeFrame: Day 1 to Day 3
measure: Urinalysis tests aggregated as number of patients outside ranges
timeFrame: Day 1 to Day 3
Other outcomes:
Locations:
city: Gières
country: France
facility: Eurofins Optimed
Study officials:
affiliation: Eurofins Optimed
name: Yves DONAZZOLO, MD
role: PRINCIPAL_INVESTIGATOR
References: